Short Interest in VolitionRX Limited (NYSEAMERICAN:VNRX) Rises By 40.0%

VolitionRX Limited (NYSEAMERICAN:VNRX) was the recipient of a significant increase in short interest during the month of January. As of January 30th, there was short interest totaling 1,565,335 shares, an increase of 40.0% from the January 15th total of 1,118,479 shares. Approximately 1.3% of the company’s shares are sold short. Based on an average trading volume of 2,494,809 shares, the short-interest ratio is presently 0.6 days. Based on an average trading volume of 2,494,809 shares, the short-interest ratio is presently 0.6 days. Approximately 1.3% of the company’s shares are sold short.

VolitionRX Price Performance

VolitionRX stock traded down $0.01 during mid-day trading on Friday, reaching $0.23. 1,322,068 shares of the company traded hands, compared to its average volume of 2,251,357. VolitionRX has a 52-week low of $0.21 and a 52-week high of $0.94. The firm’s 50 day moving average price is $0.27 and its 200 day moving average price is $0.44. The firm has a market capitalization of $30.73 million, a price-to-earnings ratio of -0.99 and a beta of 1.29.

VolitionRX Company Profile

VolitionRX, traded as VNRX on the NYSE American exchange, is a pioneering life sciences company focused on the development and commercialization of minimally invasive diagnostic tests for the early detection of cancer and other diseases. Utilizing proprietary technology to analyze circulating nucleosomes in blood samples, the company’s platform identifies disease-specific epigenetic and biochemical signatures. By offering blood-based screening solutions, VolitionRX aims to deliver alternatives to invasive, costly and time-consuming procedures, potentially improving patient outcomes through earlier diagnosis.

The company’s flagship product suite, branded as Nu.Q, comprises assays designed to detect biomarkers associated with a range of malignancies, including colorectal, lung and pancreatic cancers, as well as other systemic conditions.